Listed by the USPTO as ALSOMAIRY, SARAH ABDOALATIF
Tech Center 1600 • Art Units: 1600 1642 1643 1646
This examiner grants 57% of resolved cases
ALSOMAIRY, SARAH ABDOALATIF examines in tech center 1600 and art unit 1600. Across 155 resolved cases, the allowance rate is 57.4%, while the median time to allowance is 1223 days. The profile shows a 30.7% interview lift, making interview preparation a notable prosecution consideration in this record. The timing figure also indicates that applicants should plan for a process extending across multiple examination stages.
Merus N V, Hoffmann-La Roche Inc., and Janssen Pharmaceuticals Inc. are the listed leading companies. The listed firms are STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., Antheros Legal Advisors LLP, and GATES & COOPER LLP (General). For practitioners, the data supports pairing early interview planning with a response strategy that can preserve claim scope during a lengthy prosecution timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18668810 | COMBINATION THERAPY OF ANTI-TYRP1/ANTI-CD3 BISPECIFIC ANTIBODIES AND TYRP1-SPECIFIC ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18771839 | Combination Therapies with Anti-CD38 Antibodies | Non-Final OA | Janssen Biotech, Inc. |
| 17618240 | ENGINEERED OFF-THE-SHELF IMMUNE CELLS AND METHODS OF USE THEREOF | Final Rejection | University of Southern California |
| 17704746 | METHODS AND COMPOSITIONS COMPRISING A CD93/IGFBP7 BLOCKING AGENT FOR TREATING CANCER | Final Rejection | The Regents of the University of Colorado, a body corporate |
| 17782338 | A T cell-based immunotherapy for central nervous system viral infections and tumors | Final Rejection | YALE UNIVERSITY |
| 17596118 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH COLLAGEN BINDING DRUG CARRIERS | Non-Final OA | The University of Chicago |
| 18421751 | mRNA THERAPY WITH REDUCED IMMUNE REACTOGENICITY | Non-Final OA | Acuitas Therapeutics Inc. |
| 18279380 | METHODS OF ENHANCING ANTIBODY THERAPIES | Final Rejection | UNIVERSITY OF IOWA RESEARCH FOUNDATION |
| 18818418 | HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF | Non-Final OA | Nectin Therapeutics Ltd. |
| 18667742 | NOVEL COMBINATIONS FOR ANTIGEN BASED THERAPY | Non-Final OA | Diamyd Medical AB |
| 18666375 | METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE-RELATED BRONCHIOLITIS OBLITERANS SYNDROME USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY | Non-Final OA | Syndax Pharmaceuticals, Inc. |
| 17759195 | Conditionally Active Anti-Her2 Antibodies, Antibody Fragments Their Immunoconjugates And Uses Thereof | Final Rejection | BioAtla, Inc. |
| 18596492 | ANTI-SARS-COV-2 ANTIBODY COMPOSITIONS AND USES THEREOF | Non-Final OA | MABLOC, LLC |
| 17741275 | ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF | Final Rejection | Werewolf Therapeutics, Inc. |
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | Final Rejection | SEAGEN INC. |
| 17759728 | MEANS AND METHOD FOR MODULATING IMMUNE CELL ENGAGING EFFECTS | Final Rejection | Merus N.V. |
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | Final Rejection | Merus N.V. |
| 18507904 | METHODS OF TREATING GRAFT VERSUS HOST DISEASE | Final Rejection | ADIENNE S.A. |
| 17906000 | VARIANTS OF SAC7D AND THEIR USE IN CANCER THERAPY | Final Rejection | AFFILOGIC |
| 17904890 | EX VIVO GAMMA DELTA T CELL POPULATIONS | Non-Final OA | GAMMADELTA THERAPEUTICS LIMITED |
| 18159887 | CHIMERIC ANTIGEN RECEPTOR COMPRISING CO-STIMULATORY RECEPTOR AND APPLICATION THEREOF | Final Rejection | SHANGHAI LONGYAO BIOTECHNOLOGY INC., LTD. |
| 17955743 | Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis | Final Rejection | Wuhan Ktai Biotechnology Company Limited |
| 17294030 | STABLE LIQUID COMPOSITION COMPRISING PROTEIN | Non-Final OA | SAMSUNG BIOEPIS CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.4% of resolved applications examined by Sarah Abdoalatif Alsomairy were allowed (155 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +30.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sarah Abdoalatif Alsomairy took 1,223 days on average from filing to allowance.
Sarah Abdoalatif Alsomairy examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
